Quiddity Leaderboard CSI Medical Dec26: Expectations Have Changed; US$301mn One-Way
There are three index members failing the liquidity test by narrow margins and they should be monitored until the end of the reference period.
17 Views
Primer: Beijing Wantai Biological Phar (603392 CH) - Aug 2026
Beijing Wantai has experienced a dramatic financial downturn, shifting from high profitability in 2023 to significant losses, primarily due to...
95 Views
Quiddity Leaderboard CSI Medical Dec26: Expected ADDs Are Underperforming Expected DELs
The current expected ADDs have underperformed the current expected DELs in the last month. This is another example of the negative momentum in some...
181 Views
Quiddity Leaderboard CSI Medical Dec26: 6 ADDs/DELs Expected; US$236mn One-Way Flows
Most expected ADDs/DELs have between 1x-4x ADV to trade and flow sizes of US$25mn-US$45mn. Beijing Wantai Bio (603392 CH) is the most significant...
177 Views
APAC Healthcare Weekly (April 6)- Nippon Shinyaku, Shionogi, Beigene, Celltrion, Mesoblast, Lupin
Nippon Shinyaku and Shionogi are filing for new drugs. Beigene dropped a phase 3 oncology asset. Mesoblast is about to start treatment with...
862 Views